3.7600 0.00 (0.00%)
After hours: 4:00PM EDT
|Bid||3.7600 x 2200|
|Ask||3.7700 x 1200|
|Day's Range||3.7600 - 4.1400|
|52 Week Range||3.2200 - 13.9700|
|Beta (3Y Monthly)||1.05|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.33|
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 10.) The Medicines Company (NASDAQ: MDCO ) Ra ...
This cancer-fighting biotech was one of the early companies to commit to The Cove at Oyster Point; now it may sublease some or all of its space.
Five Prime Therapeutics, Inc. (FPRX), a clinical-stage biotechnology company focused on discovering and developing immune modulators and precision therapies for solid tumor cancers, announced today a corporate restructuring to extend the company’s cash runway without impacting or delaying the data timelines of its clinical programs. The company will retain a small research group focused on advancing three wholly-owned, late-stage research assets and will increasingly rely on outsourcing and contracted capabilities. “My immediate focus as CEO has been to conduct a review of Five Prime’s operations with the goal of ensuring long-term sustainability and value creation,” said William Ringo, Chairman and Interim Chief Executive Officer of Five Prime Therapeutics.
(Bloomberg) -- Large swings in market value are common in the biotech industry, and analysts covering the sector have no shortage of ideas on which stocks could be next to pop.Wall Street’s biggest bulls expect 159 of the 218 stocks in the Nasdaq Biotech Index to double over the next year, data compiled by Bloomberg show. Eleven analysts even see potential for members of the index to be worth ten times or more than their current value in 12 months.On Wall Street, where selling stock is the business, analysts are not known for excessive pessimism -- sell ratings are generally assigned to less than 10% of companies. Perhaps nowhere is confidence in the future more pronounced than in biotech, where volatility is the rule among early stage companies and analysts can make their name by getting one giant rally right.Investors have gotten hefty payouts by sticking with calls on companies like Amarin Corp., Eidos Therapeutics Inc. and Spark Therapeutics Inc. At the same time, it’s worth noting that big blow ups are not uncommon, even when Wall Street is unabashedly optimistic. Analysts were whipsawed in recent months by Biogen Inc.’s Alzheimer’s flop, Tocagen Inc.’s failed brain cancer drug, Aquestive Therapeutics Inc.’s generic battles and Nektar Therapeutics’ cancer-drug woes.Here are some of their biggest calls right now:Proteostasis Therapeutics Inc.Cantor Fitzgerald’s Elemer Piros has a $14 price target that is roughly double the rest of the Street and more than 1,600% above where the stock currently trades. Proteostasis is a penny stock after falling 90% from last year’s peak, but Piros remains bullish on the company’s cystic fibrosis portfolio. Bottom line: While all four analysts tracked by Bloomberg hold buy-equivalent ratings, Cantor expects Proteostasis can compete with juggernaut Vertex Pharmaceuticals Inc., which is a hefty statement.Five Prime Therapeutics Inc.RBC Capital analyst Kennen Mackay has held a $50 price target on Five Prime Therapeutics since November 2017 despite the stock’s 90% drop since then. The next closest price target among his peers is $16, which would still mean the shares more than quadruple in the next year. Bottom line: Late-stage study results in the first half of next year are key for RBC’s big call, although Five Prime also has drug data coming up in November that could spark some optimism among investors.Kala Pharmaceuticals Inc.Wedbush’s Liana Moussatos has been among the company’s biggest fans since launching coverage back in 2017. Her price target of $51 implies a more than 1,300% gain from the current share price and is almost double the stock’s peak level from two years ago. Bottom line: Data for Kala’s dry eye drug later this year will be a key catalyst to revive the stock.Adamas Pharmaceuticals Inc.JMP analyst Jason Butler likes the company’s drug for uncontrolled movements in patients with Parkinson’s disease despite the stock’s continued slide since May 2018. Butler sees an inflection in sales of the drug, Gocovri, in the back half of this year ahead of late-stage clinical results due in coming months. Bottom line: The bull case depends on Gocovri after slowing prescription growth raised questions over the last few quarters. Analysts see a longer term benefit from a recent shakeup in the company’s management team.Acorda Therapeutics Inc.Cowen analyst Philip Nadeau’s call for Acorda shares to be worth $30 -- compared to less than $3 currently -- is a stark contrast from the rest of Wall Street. He’s the only buy rating, and the stock has fallen 86% in the last year. His position on the stock has weighed on his overall returns, with his recommendations losing 24% of their value in the past year compared to a 15% decline for peers, according to data compiled by Bloomberg. Bottom line: Nadeau expects a pickup in sales for Acorda’s Inbrija through year-end after struggles with limited reimbursement access.Foamix Pharmaceuticals LtdFoamix is another big call for Cowen, this time from Ken Cacciatore, who sees a ten-fold gain in the share price for the maker of acne drugs and birth control. Notably, Cowen has acted on each of the company’s offerings since at least 2014. Bottom line: Foamix has universal buy ratings from analysts while the shares have lost about half their value in the past year. A key aspect of the bull thesis is Foamix’s ability to spark interest from larger companies, although there has been little evidence of traction on that so far.To contact the reporter on this story: Bailey Lipschultz in New York at firstname.lastname@example.orgTo contact the editors responsible for this story: Catherine Larkin at email@example.com, Jennifer Bissell-LinskFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
- Results Provide First Clinical Demonstration of B7-H4 as a Potential Therapeutic Target and Continue to Support FPA150’s Greatest Potential in Combination Therapy -
Five Prime Therapeutics, Inc. (FPRX), a clinical-stage biotechnology company focused on discovering and developing immune modulators and precision therapies for solid tumor cancers, announced today that its Board of Directors has appointed William “Bill” Ringo as Interim Chief Executive Officer, effective immediately. Mr. Ringo will succeed Chief Executive Officer and Board Member Aron Knickerbocker, who has resigned from the company to pursue new challenges and opportunities. Mr. Ringo will continue to serve as Chairman of Five Prime’s Board of Directors.
If you want to know who really controls Five Prime Therapeutics, Inc. (NASDAQ:FPRX), then you'll have to look at the...
Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of -15.12% and -39.71%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
How far off is Five Prime Therapeutics, Inc. (NASDAQ:FPRX) from its intrinsic value? Using the most recent financial...
Five Prime Therapeutics, Inc. (FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced the appointment of Lori Lyons-Williams to its Board of Directors. Ms. Lyons-Williams is an industry leader with 20 years of experience launching and commercializing innovative pharmaceutical products. “We welcome Lori to our board and look forward to her contributions as we continue to build Five Prime by advancing our differentiated clinical pipeline, leveraging our discovery platform, and collaborating with our strategic alliance partners,” said Aron Knickerbocker, Chief Executive Officer of Five Prime Therapeutics.
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]
Five Prime Therapeutics Inc NASDAQ/NGS:FPRXView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low and declining * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for FPRX with fewer than 5% of shares on loan. Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on June 14. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding FPRX is favorable, with net inflows of $2.40 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Five Prime Therapeutics, Inc. (FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced the departure of Dr. Sheila Gujrathi from the company’s board of directors. Dr. Gujrathi has served as a board member of Five Prime since December 2015 and is stepping down from the board to focus on her role as President and Chief Executive Officer of Gossamer Bio, Inc., a biopharmaceutical company that she co-founded in 2017 and that completed its initial public offering in February 2019.
Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics today ann
Five Prime Therapeutics, Inc. (FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today presented monotherapy data from the dose escalation portion of the Phase 1a/1b clinical trial of FPA150 in patients with advanced solid tumors. The data are the first presentation of FPA150 results and include safety and pharmacokinetics results from the Phase 1a monotherapy dose escalation portion of the study. The Phase 1a monotherapy portion of the study is being conducted in patients with advanced solid tumors, and the Phase 1b monotherapy expansion is enrolling patients with breast, ovarian and endometrial tumors that overexpress B7-H4.
Five Prime Therapeutics, Inc. (FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced the appointment of Carol Schafer to its Board of Directors. Ms. Schafer is an industry leader with more than 25 years of investment banking and equity capital markets experience in the biotechnology sector. “We welcome Carol to our board and look forward to her contributions as we continue to build Five Prime by advancing our differentiated clinical pipeline, leveraging our discovery platform, and collaborating with our strategic alliance partners,” said Aron Knickerbocker, Chief Executive Officer of Five Prime Therapeutics.